Pharma Pulse: Drug Tariffs Threaten Access, Pediatric Flu Raises Vaccination Concerns, and AbbVie Files NDA for Tavapadon

'Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and today we’re covering drug tariff risks, new concerns around pediatric flu, and AbbVie’s latest regulatory filing.

• The Trump administration will be imposing a 100% tariff on branded drugs imported into the US, expected to take effect Oct. 1. This has sparked alarm across the pharmaceutical sector, with analysts warning it could drive up costs for patients and disrupt global supply chains.
• New research highlights a troubling link between pediatric influenza and neurological complications, including seizures and encephalopathy. The findings have raised concerns about vaccination gaps, as flu shot uptake among children remains below public health targets. Experts stress that improved vaccination coverage is critical to reducing both the direct and long-term impacts of pediatric flu.
• Lastly, in regulatory news, AbbVie has submitted a new drug application to the FDA for tavapadon, an investigational therapy for Parkinson’s disease. The drug targets dopamine receptors with the aim of improving motor function and potentially reducing side effects associated with current treatments. If approved, tavapadon could represent a meaningful addition to the limited options available for patients managing this chronic, progressive condition.

From drug tariffs and urgent vaccination concerns to advances in Parkinson’s treatment, these stories reflect the intersection of politics, public health, and innovation shaping pharma today.

That’s it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access and care delivery, visit pharmaceuticalcommerce.com.

Thanks for listening—until next time, stay well and stay informed.

You can catch Pharma Pulse directly on Audioboom, Spotify, or iHeart.